Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
$0.01
$0.00
▼
$0.11
$16K-0.4429,258 shs2,008 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.01
$0.02
$0.01
▼
$4.21
$198K0.13248,621 shs3,714 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%0.00%-40.00%-99.32%-99.70%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-6.52%-8.51%-21.82%-85.32%-99.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
$0.01
$0.00
▼
$0.11
$16K-0.4429,258 shs2,008 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.01
$0.02
$0.01
▼
$4.21
$198K0.13248,621 shs3,714 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%0.00%-40.00%-99.32%-99.70%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-6.52%-8.51%-21.82%-85.32%-99.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00
N/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.06M0.04N/AN/A$2.46 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%11/12/2026 (Estimated)
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$2.25N/AN/AN/A-825.01%-482.05%-88.90%11/5/2026 (Estimated)

Latest PRPH and BPTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$2.05N/AN/AN/A$11.98 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.14
0.14
0.14

Institutional Ownership

CompanyInstitutional Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%

Insider Ownership

CompanyInsider Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1053.90 million5.73 millionNo Data
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13023.00 million5.44 millionNo Data

Recent News About These Companies

Shyam Venkatesan reports 5.48 percent stake in ProPhase Labs stock
October 21, 2026  |  ad-hoc-news.deA
ProPhase Labs stock reports a 29.4 percent revenue decline
October 1, 2026  |  ad-hoc-news.deA
ProPhase Labs stock holds as latest figures shape the risk profile
September 22, 2026  |  ad-hoc-news.deA
ProPhase Labs Delays Quarterly SEC Filing
August 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-delays-quarterly-sec-filing?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Inc.
July 16, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/prph/financials/cash-flow
ProPhase Labs Announces Immediate Resignation of Board Member
June 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PRPH/pressreleases/36984840/prophase-labs-announces-immediate-resignation-of-board-member/
ProPhase Labs Delays Quarterly Financial Filing
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-delays-quarterly-financial-filing?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
April 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/15/3274530/0/en/prophase-labs-reports-year-end-2025-results-highlights-accelerating-settlement-activity-and-investment-ready-crown-medical-collections-platform.html
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
March 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/prophase-labs-provides-business-highlighting-120000129.html
ProPhase Labs Explores Strategic Options for BE-Smart Test
February 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-explores-strategic-options-for-be-smart-test?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs, Inc.: ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart and Advances Crown Medical Collections Initiative
February 3, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67599969-prophase-labs-inc-prophase-labs-initiates-potential-sale-or-strategic-partnership-of-be-smart-and-advances-crown-medical-collections-initiative-399.htm
ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
February 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/prophase-labs-initiates-potential-sale-120000291.html
ProPhase Labs initiates potential sale or strategic partnership of BE-Smart
February 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4546120-prophase-labs-initiates-potential-sale-or-strategic-partnership-of-be-smart
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd
February 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/join-prophase-labs-exclusive-live-investor-webinar-and-q-a-session-on-february-3rd-1035773219
ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture
January 26, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prophase-labs-provides-crown-medical-collections-update-250-insurance-payors-engaged-approximately-50-matters-in-advanced-settlement-posture-1035745250
ProPhase Labs Secures Flexible $10 Million Equity Facility
January 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-secures-flexible-10-million-equity-facility?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Uplists from Pink Sheets to OTC Market
January 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prophase-labs-uplists-from-pink-sheets-to-otc-market-1035736260
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
January 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/05/3212517/0/en/prophase-labs-provides-update-on-convertible-debt-conversions-capital-structure-and-underlying-asset-value.html
ProPhase Labs faces NASDAQ delisting, plans appeal, OTC move
January 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/prophase-labs-faces-nasdaq-delisting-plans-appeal-otc-move/ar-AA1TtNWj
ProPhase Labs signs non-binding LOI for proposed reverse merger with ABL
December 19, 2025  |  msn.comhttps://www.msn.com/en-us/money/mergers-and-acquisitions/prophase-labs-signs-non-binding-loi-for-proposed-reverse-merger-with-abl/ar-AA1SGkg8

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.0003 0.00 (0.00%)
As of 10/26/2026 02:10 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.0086 0.00 (0.00%)
As of 10/27/2026 03:12 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas